BACKGROUND Patients with diabetes mellitus (DM) have an increased risk of adverse outcomes after coronary artery
there is a doubling of the age-adjusted prevalence of coronary heart disease, and the risk of death is between 2 and 4 times higher than in those without DM (4, 5) . Approximately 25% of all U.S. patients who undergo multivessel coronary revascularization have DM (6).
T1DM and T2DM have different underlying pathophysiology. T1DM is usually characterized by onset at an early age, in which the underlying cause is autoimmunity and destruction of the insulin-producing b cells, leading to insulin deficiency. By contrast, T2DM is characterized by an adult onset of hyperinsulinemia that is due to insulin resistance and, as a consequence, a slow progression of hyperglycemia.
T2DM is associated with obesity, and its incidence increases with age (7, 8) .
A number of studies have investigated the impact of DM on prognosis after coronary artery bypass grafting (CABG) (9) (10) (11) (12) . The categorization of DM in these studies has varied from dividing patients according to only the presence or absence of DM (10) (11) (12) to, more specifically, insulin-treated or not insulintreated diabetes (9) . Results from these studies have been conflicting: some demonstrating an association with adverse outcome (11) , and others finding no independent association with outcome (10, 12) . In another study, it was reported that compared with non-insulin-treated diabetes, those with insulintreated diabetes had an increased long-term risk of death (9) . To the best of our knowledge, there is only 1 study that has categorized CABG patients into T1DM and T2DM (13) . In that study, the authors found an association with death and myocardial infarction (MI) for both T1DM and T2DM.
On the basis of recent findings, the quality of care has improved in patients with T1DM, and consequently, there is a paucity of evidence regarding prognosis in contemporary patients with T1DM and coronary artery disease. Recently, the American Heart Association and the American Diabetes Association published a scientific statement calling for more studies in patients with T1DM and cardiovascular disease (14) . Consequently, we performed a nationwide population-based cohort study in patients who underwent CABG in Sweden over a period of 11 years to investigate the importance of T1DM and T2DM regarding the long-term risk of death. T2DM was defined as DM treated with diet or oral hypoglycemic agents alone, or age >40 years at onset and treated with insulin alone or in combination with oral hypoglycemic agents (17 We used Cox regression to estimate the risk of allcause mortality or a combined endpoint (all-cause mortality or hospital stay for MI, heart failure, stroke, or repeat revascularization) in patients with T1DM or T2DM in a comparison with reference patients without diabetes. We calculated crude and multivariable adjusted hazard ratios (HRs) and 95% confidence intervals (CIs). We included all the variables listed in Table 1 Table 1 . A total of 39,235 patients with a mean age of 67 years were included, of whom 21% (8,170 of 39,235) were women. 1.66 to 2.84), respectively ( Table 3 ). The absolute risk of death in women with T2DM was higher than that in men with T2DM (22% vs. 18%). However, after adjustment for confounders, the relative risks were similar for both men and women with T2DM ( Table 3) .
METHODS

RESULTS
Patient characteristics are presented in
Similar sex-specific associations between types of diabetes were also found for death and MACE combined as outcome ( Table 3) .
DISCUSSION
In a large nationwide cohort of patients who underwent a first isolated CABG during an 11-year period in Sweden, we found that patients with T1DM had a risk of death after CABG double that of patients without DM. There was a small, but statistically significant, Values are n (%) or mean AE SD. End-stage renal disease was defined as eGFR <15 ml/min/1.73 m 2 or on dialysis/renal transplant.
CABG ¼ coronary artery bypass grafting; eGFR ¼ estimated glomerular filtration rate; PCI ¼ percutaneous coronary intervention; T1DM ¼ diabetes mellitus type 1; T2DM ¼ diabetes mellitus type 2.
JACC VOL. 65, NO. 16, 2015 Holzmann et al. A number of either population-based or randomized trials have reported on the association between DM and the risk of cardiovascular disease (14) . However, most of these studies have either only included patients with T2DM or have not made any distinction between T1DM and T2DM, and thus have analyzed patients as being merely diabetic or nondiabetic. This also holds true for previous studies on the importance of DM for prognosis after CABG, which may explain the conflicting results found in previous studies (7) (8) (9) (10) (11) . To the best of our knowledge, only 1 previous study has investigated the association between T1DM and T2DM and outcomes after CABG (11), wherein both subtypes of DM were associated with the combined outcome of death or MI. That study included only 50 patients with T1DM, and the inclusion period was 1980 to 1995. Thus, considering the recent rather steep decline in cardiovascular events and death associated with DM (19) (20) (21) (22) , and the small number of events reported in that study, we believe that the findings may not be applicable to contemporary cohorts of CABG patients.
The 2 main findings in our study were that T1DM was associated with a doubling of mortality, but also that patients with T2DM had only a minimally increased risk of death in comparison with nondiabetic patients (Central Illustration). Furthermore, patients with T1DM were more likely than patients with T2DM or without diabetes to have comorbidities, such as chronic kidney disease, end-stage renal disease, peripheral vascular disease, or heart failure, which all have been associated with a worse prognosis in diabetic patients who undergo CABG (9,10). However, even after adjustment for these risk factors, the association between T1DM and adverse outcome was significant. One of the main differences between the 2 subtypes of diabetes is the duration of the disease. In the present study, the difference in mean duration of disease between patients with T1DM and T2DM was >30 years. This fact may help explain the differences seen in prognosis between the 2 subtypes of diabetes, because the duration of exposure to risk factors and comorbidities was considerably longer in patients with T1DM than in those with T2DM. In addition, HbA 1c levels were higher in patients with T1DM than in those with T2DM, revealing poorer glycemic control in patients with T1DM. The association between glycemic control and micro-and macroangiopathy seems to be more significant in T1DM than in T2DM (16, 22) . Although we do not have any data on microvascular complications, the increase in HbA 1c levels together with the longer duration of diabetes seen in T1DM might explain our findings.
Interestingly, in a recently published study, HbA 1c levels in patients with insulin-treated DM who underwent PCI were not related to mortality (23) . In the JACC VOL. 65, NO. 16, 2015 Holzmann
Diabetes and Prognosis After CABG than that for patients without DM, thus diluting the differences in risk between those with T2DM and those without DM.
It is generally thought that women with DM have a higher relative risk of cardiovascular events than men with DM (12, 27, 28) . However, recent studies have challenged this statement and have found similar risks in men and women (19) . In the present study, we found no sex differences in relative risks between outcomes and both T1DM and T2DM cohorts.
By using the National Diabetes Register, we were able to classify all patients according to the type of DM, and thus investigate the importance of the 2 subtypes for prognosis. The information used for categorization into T1DM and T2DM has been shown to have high validity (16) . To the best of our knowledge, this was the first study of a contemporary cohort of patients undergoing CABG where the association between subtypes of DM and prognosis were investigated. Moreover, we also had information on the characteristics that distinguish T1DM from T2DM in general, that is, duration of diabetes and glycemic control, which allowed us to speculate to some extent on potential mechanisms responsible for the differences seen in prognosis among patients with T1DM
and T2DM. The nationwide population-based design allowed for a large study population, and the rather long follow-up led to a large number of events, which
gave us the opportunity to analyze additional clinically relevant outcomes, such as cause-specific mortality and need for repeat revascularization. The high-quality Swedish national registers from which we derived the study population and retrieved patient characteristics and outcomes have been found to have high validity in previous studies (15, 29, 30) .
Furthermore, as the coverage of these registers is virtually complete and countrywide, the risk of misclassification of disease or outcome was small, and there was no loss to follow-up. In addition, considering the nationwide design of our study and the recent study period, reflecting current standard of care, we believe that our results have a high external validity and are applicable to other patients with DM undergoing CABG in countries with a similar level of healthcare.
STUDY LIMITATIONS. We did not have any information on patients with DM who underwent PCI instead of CABG for multivessel disease. Therefore, our results cannot be generalized to this group of patients.
However, a number of early and recent studies have investigated which method of revascularization (PCI or CABG) is preferred in patients with DM (31). There is a general consensus that CABG is superior to PCI in patients with DM and multivessel disease, particularly in patients with more complex coronary artery disease, provided that they are candidates for cardiac surgery (32) . Thus, we believe that our findings are of great importance for patients with DM who may need to undergo multivessel revascularization.
There may have been misclassification of glycemic control among patients without DM. This was Values are n events/n patients (%) or HR (95% CI). All variables listed in Table 1 were included as covariates in the final multivariable model. *MACEþdeath is defined as a combined endpoint of death, or rehospitalization for myocardial infarction, heart failure, or stroke, or repeat revascularization.
CI ¼ confidence interval; HR ¼ hazard ratio; MACE ¼ major adverse cardiac event(s); other abbreviations as in Table 1 . a potential limitation because it has been shown that a large proportion of patients with acute coronary syndromes have undetected T2DM or glucose intolerance (24) .
CONCLUSIONS
We found that patients with T1DM had a doubling of the risk of death, whereas patients with T2DM had almost a similar risk of death as patients without diabetes in a nationwide cohort of 39,235 patients who underwent CABG. Our data indicate that patients with T1DM are at high risk for adverse outcome after CABG and should be closely followed up, and that all possible measures to mitigate their risk of death or recurrent cardiovascular events should be instituted.
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